Multiple Myeloma, Phase II
A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma
Volunteers
Health Professionals
What is the purpose of this trial?
The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Alessia Donadio, MD
- Alexis Walker
- Alfredo Axtmayer
- Alison Johnson
- Amy Pugliese
- Andrea Brennan
- Andrea Silber, MD
- Anne Chiang, MD, PhD
- Armand Russo, MD
- Beverly Drucker, MD, PhD
- Carolyn Demsky, APRN
- Catherine Wei, MD
- Clarice Grens
- D. Barry Boyd, MD, MS
- Elan Gorshein, DO, JD, MPH
- Emily Collier, MD
- Emily Kopas, APRN, OCN
- Francesca Montanari, MD
- Francine Foss, MD
- Harold Tara Jr, MD
- Iris Isufi, MD
- Jane Kanowitz, MD
- Jeremy Kortmansky, MD
- Johanna LaSala, MD
- Jose Morales-Marin
- Justin Persico, MD
- Karishma Mehra, MBBS
- Kathleen Fenn, MD
- Kayla Martello
- Kerri Ann Rall
- Kristen Hoxie
- Larisa Fleysher
- Laura Sabourin
- Leena Rahmat
- Lisa Rivera
- Lohith Gowda, MD, MRCP
- M. Sung Lee, MD
- Madeline Santiago
- Manoj M Pillai, MBBS
- Marianne Davies, NP, DNP, MSN, BSN
- Maureen McGlennon
- Meifeng Shen
- Michael Burke
- Michael Cohenuram, MD
- Michael Hurwitz, MD, PhD
- Neal Fischbach, MD
- Nicholas Blondin, MD
- Osarugue Otasowie
- Pawan Karanam, MD
- Sara Anastasio, RN
- Sarah Carlson
- Sarah Elizabeth Schellhorn, MD
- Stephanie Kacik
- Stuart Seropian, MD
- Su Hsien Lim, MD
- Sudhanshu Mulay, MD
- Syed Ali
- Syed Bilgrami, MBBS
- Tara Anderson
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Zia Rahman, MD
- Last Updated01/05/2025
- Study HIC#2000036816